🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Dara L. Aisner

University of Colorado Cancer Center

ORCID: 0000-0001-5203-5932

Also affiliated with University of Colorado Anschutz Medical Campus, University of Colorado Denver

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 7%percentile
0.104Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2188
Top 78%
0.104DataRank
Top 78%1 citations

Laura M. Yee, Ting-Chia Chang, Jeffrey Sklar, Guoren Yang, Jiadi Wen +80 more

Papers

Driven by 11 papers — median percentile 22. Top paper: “Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study”.

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study

Journal of Clinical Oncology(2024)10.1200/jco.24.00071
N/A
1.4DataRank · unranked
60 citations

Anatoly Urisman, Matthew A. Gubens, Claire K. Mulvey, Greg M. Allen, Stephen Shiboski +19 more

Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway

npj Precision Oncology(2023)10.1038/s41698-023-00349-0
N/A
0.600DataRank · unranked
15 citations

Anh T. Le, Amanuail Gebregzabheir, Hala Nijmeh, Gregory B. Reis, Melanie Mandell +8 more

A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2188
Top 78%
0.104DataRank
Top 78%1 citations

Laura M. Yee, Ting-Chia Chang, Jeffrey Sklar, Guoren Yang, Jiadi Wen +80 more

Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology

Frontiers in Oncology(2022)10.3389/fonc.2021.788245
N/A
0DataRank · unranked
6 citations

Yunan Nie, Dara L. Aisner, David Ross Camidge, Tejas Patil

Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer

Journal of Clinical Investigation(2023)10.1172/jci160330
N/A
0DataRank · unranked
21 citations

Ruichen Rong, Donghan M. Yang, Junya Fujimoto, Justin A. Bishop, Shirley Yan +15 more

Comparison of Tissue Molecular Biomarker Testing Turnaround Times and Concordance Between Standard of Care and the Biocartis Idylla Platform in Patients With Colorectal Cancer

American Journal of Clinical Pathology(2020)10.1093/ajcp/aqaa044
N/A
0DataRank · unranked
14 citations

M Rabie Al Turkmani, Michael Suriawinata, Michael J Babcock, Kristi Mitchell, Yi Ding +34 more

The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations

Lung Cancer(2024)10.1016/j.lungcan.2024.108040
N/A
0DataRank · unranked
10 citations

Dexiang Gao, Alexander Watson, M Sakamoto, Yunan Nie, A.J. Gibson +13 more

The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100637
N/A
0DataRank · unranked
8 citations

Alyse Staley, Yunan Nie, M Sakamoto, Margaret Stalker, James Jurica +17 more

The Genomics Organization for Academic Laboratories (GOAL): A vision for a genomics future for academic pathology

Academic Pathology(2023)10.1016/j.acpath.2023.100090
N/A
0DataRank · unranked
5 citations

Christopher D. Gocke, Dan Jones, Melvin Limson, Jennifer J.D. Morrissette, Jeremy P. Segal +1 more

Clinical and molecular characterization of a multi-institutional cohort of pediatric spinal cord low-grade gliomas

Neuro-Oncology Advances(2020)10.1093/noajnl/vdaa103
N/A
0DataRank · unranked
9 citations

Liana Nobre, Kristen Campbell, Kurtis D. Davies, Scott Ryall, Dara L. Aisner +15 more

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC

npj Precision Oncology(2021)10.1038/s41698-021-00231-x
N/A
0DataRank · unranked
11 citations

Tejas Patil, Anh T. Le, Kurtis D. Davies, Peter Brzeskiewicz, Hala Nijmeh +5 more